Cantor Fitzgerald Downgrades Monopar Therapeutics (MNPR) to Neutral

August 13, 2026 4:24 AM

Cantor Fitzgerald analyst Kirsten Kluska downgraded Monopar Therapeutics (NASDAQ: MNPR) from Overweight to Neutral with a price target of $119.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found